MET and non-small cell lung carcinoma: The prognostic impact of MET exon 14 skipping has not yet been studied extensively, but previously untreated patients displaying MET dysregulation in NSCLC (due to MET exon 14 skipping, MET amplification, or both) display bad prognosis (Awad, 2016).